Kedalion Therapeutics Secures Series B Funding And Announces Signing Of Option To Acquire Agreement
Nov 15, 2021•over 3 years ago
Round Type
series b
Description
Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStreamTM technology. This agreement follows a Feasibility Study agreement with the AcuStreamTM technology signed earlier this year. The subsequent feasibility study has been completed with successful results